Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425392 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
A Phase 3 study of Pneumococcal Vaccines, sponsored by Vaxcyte.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 20
- Study locations
NCT07425392 is a Phase 3 study of Pneumococcal Vaccines that is actively recruiting participants, run by Vaxcyte. The registered enrollment target is 720 participants, below the 1,443-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07425392, a Phase 3 study of Pneumococcal Vaccines, is actively recruiting participants, sponsored by Vaxcyte.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Conditions Studied
Interventions
- BIOLOGICAL 31-valent pneumococcal conjugate vaccine
- BIOLOGICAL PCV20
Study Locations (20)
Florida
- CenExel (RCA) - Hollywood
- Eximia (Health Awareness) - Jupiter
- Eximia (Health Awareness) - Port Saint Lucie
- Precision Clinical Research - Sunrise
- The Villages - The Villages
Arizona
- Chinle Center for Indigenous Health - Chinle
- Avacare (CCT Research) - Phoenix
- Whiteriver Center for Indigenous Health - Whiteriver
Missouri
- AMR - Kansas City
- DelRicht Research (Command Family Medicine) - Springfield
New Mexico
- Center of American Indian Health - Gallup
- Shiprock Center for Indigenous Health - Shiprock
Connecticut
- Chase Medical Research - Waterbury
Georgia
- DelRicht Clinical Research - Stockbridge
Indiana
- Velocity Clinical Valparaiso - Valparaiso
Kansas
- Johnson County Clin-Trials, LLC - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07425392
The ClinicalTrials.gov registry entry for NCT07425392 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,443-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (50% lower). The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 2 interventions - of which 31-valent pneumococcal conjugate vaccine is the first listed.
NCT07425392 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT07425392 about?
NCT07425392 is a clinical study titled "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination". The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
What is the current status of trial NCT07425392?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2026-02-09. Estimated completion is 2027-03.
What conditions does trial NCT07425392 study?
This clinical trial studies the following conditions: Pneumococcal Vaccines.
What interventions are being tested in trial NCT07425392?
The interventions under investigation include: 31-valent pneumococcal conjugate vaccine (BIOLOGICAL), PCV20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07425392?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07425392 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
RECRUITING · Phase 3
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
COMPLETED · Phase 2
-
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.